Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Cash from Financing Activities (2016 - 2025)

Guided Therapeutics' Cash from Financing Activities history spans 15 years, with the latest figure at $181000.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 53.83% year-over-year to $181000.0; the TTM value through Sep 2025 reached $1.0 million, up 71.33%, while the annual FY2024 figure was $916000.0, 3716.67% up from the prior year.
  • Cash from Financing Activities for Q3 2025 was $181000.0 at Guided Therapeutics, down from $239000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $2.9 million in Q3 2022 and bottomed at -$154000.0 in Q3 2023.
  • The 5-year median for Cash from Financing Activities is $181000.0 (2025), against an average of $350789.5.
  • The largest annual shift saw Cash from Financing Activities skyrocketed 687.88% in 2022 before it crashed 300.0% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$53000.0 in 2021, then increased by 20.75% to -$42000.0 in 2022, then skyrocketed by 566.67% to $196000.0 in 2023, then soared by 168.37% to $526000.0 in 2024, then plummeted by 65.59% to $181000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Cash from Financing Activities are $181000.0 (Q3 2025), $239000.0 (Q2 2025), and $58000.0 (Q1 2025).